TY - JOUR
T1 - The need for combination antihypertensive therapy to reach target blood pressures
T2 - What has been learned from clinical practice and morbidity-mortality trials?
AU - Struijker-Boudier, H. A J
AU - Ambrosioni, E.
AU - Holzgreve, H.
AU - Laurent, S.
AU - Mancia, G.
AU - Ruilope, L. M.
AU - Waeber, B.
PY - 2007/9
Y1 - 2007/9
N2 - Pharmacological treatment of hypertension represents a cost-effective way for preventing cardiovascular and renal complications. To benefit maximally from antihypertensive treatment blood pressure (BP) should be brought to below 140/90 mmHg in every hypertensive patient, and even lower (<130/80 mmHg) if diabetes or renal disease co-exists. Most of the time such targets cannot be reached using monotherapies. This is especially true in patients who exhibit a high cardiovascular risk. The co-administration of two agents acting by different mechanisms considerably increases BP control. Such preparations are not only efficacious, but also well tolerated, and some fixed low-dose combinations have a tolerability profile similar to placebo. This is for instance the case for the preparation containing the angiotensin-converting enzyme inhibitor perindopril (2 mg) and the diuretic indapamide (0.625 mg), a fixed low-dose combination that has recently been shown in controlled interventional trials to be more effective than monotherapies in reducing albuminuria, regressing cardiac hypertrophy and improving macrovascular stiffness. Fixed-dose combinations are becoming more and more popular and are even proposed by current hypertension guidelines as a first-line option to treat hypertensive patients.
AB - Pharmacological treatment of hypertension represents a cost-effective way for preventing cardiovascular and renal complications. To benefit maximally from antihypertensive treatment blood pressure (BP) should be brought to below 140/90 mmHg in every hypertensive patient, and even lower (<130/80 mmHg) if diabetes or renal disease co-exists. Most of the time such targets cannot be reached using monotherapies. This is especially true in patients who exhibit a high cardiovascular risk. The co-administration of two agents acting by different mechanisms considerably increases BP control. Such preparations are not only efficacious, but also well tolerated, and some fixed low-dose combinations have a tolerability profile similar to placebo. This is for instance the case for the preparation containing the angiotensin-converting enzyme inhibitor perindopril (2 mg) and the diuretic indapamide (0.625 mg), a fixed low-dose combination that has recently been shown in controlled interventional trials to be more effective than monotherapies in reducing albuminuria, regressing cardiac hypertrophy and improving macrovascular stiffness. Fixed-dose combinations are becoming more and more popular and are even proposed by current hypertension guidelines as a first-line option to treat hypertensive patients.
UR - http://www.scopus.com/inward/record.url?scp=34547817652&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547817652&partnerID=8YFLogxK
U2 - 10.1111/j.1742-1241.2007.01302.x
DO - 10.1111/j.1742-1241.2007.01302.x
M3 - Article
C2 - 17686100
AN - SCOPUS:34547817652
VL - 61
SP - 1592
EP - 1602
JO - Medicine illustrated
JF - Medicine illustrated
SN - 1368-5031
IS - 9
ER -